| Autor: |
Anjum FR; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Anam S; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Abbas G; Melbourne Veterinary School, The University of Melbourne, Werribee, Australia., Mahmood MS; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Rahman SU; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Goraya MU; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Abdullah RM; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Luqman M; Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan., Ali A; Department of Pathology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, Pakistan., Akram MK; Queensland Alliance for Agriculture and food Innovation, The University of Queensland, Brisbane, Australia., Chaudhry TH; Department of Microbiology, Government College University, Faisalabad, Pakistan. |
| Abstrakt: |
Since the end of 2019, the emergence of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accelerated the research on host immune responses toward the coronaviruses. When there is no approved drug or vaccine to use against these culprits, host immunity is the major strategy to fight such infections. Type I interferons are an integral part of the host innate immune system and define one of the first lines of innate immune defense against viral infections. The in vitro antiviral role of type I IFNs against Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV (severe acute respiratory syndrome coronavirus) is well established. Moreover, the involvement of type I IFNs in disease pathology has also been reported. In this study, we have reviewed the protective and the immunopathogenic role of type I IFNs in the pathogenesis of MERS-CoV, SARS-CoV, and SARS-CoV-2. This review will also enlighten the potential implications of type I IFNs for the treatment of COVID-19 when used in combination with IFN- γ . |
